Neurobiological basis of quetiapine's antidepressant effect in the bipolar disorder;Bases neurobiológicas del efecto antidepresivo de la quetiapina en el trastorno bipolar

Actas Espanolas de Psiquiatria

Volumn 38, Issue 1, 2010, Pages 22-32

  Prieto, Esther ^a   Mico J A ^b   Meana, J J ^c   Majadas, S ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF CÁDIZ   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Bipolar depression; Bipolar disorder; Neurobiological basis; Quetiapine

Indexed keywords

ANTIDEPRESSANT AGENT; DIBENZOTHIAZEPINE DERIVATIVE; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; QUETIAPINE; SEROTONIN RECEPTOR;

ARTICLE; BIPOLAR DISORDER; DRUG EFFECT; HUMAN; NEUROBIOLOGY;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; HUMANS; NEUROBIOLOGY; NEUROPROTECTIVE AGENTS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN;

EID: 79952278499     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Murray CJ, López AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study. Lancet 1997:1347-52. (Pubitemid 27197536)
2. Hlastala SA, Frank E, Mallinger AG, Thase ME, Ritenoir AM, Kupfer DJ. Bipolar depression: an underestimated treatment challenge. Depress Anxiety 1997;5:73-83. (Pubitemid 28079921)
3. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7. (Pubitemid 34602935)
4. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-9. (Pubitemid 36307437)
5. Calabrese JR, Hirschfeld RM, Frye MA, Reed ML. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U. S.community-based sample. J Clin Psychiatry 2004;65:1499-504.
6. Altshuler LL, Gitlin MJ, Mintz J, Leight KL, Frye MA. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 2002;63:807-11.
7. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for U. S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007;58:85-91.
8. Ghaemi SN, Hsu DJ, Thase ME, Wisniewski SR, Nieremberg AA, Miyahara S, et al. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr Serv 2006;57:660-5.
9. Bond DJ, Noroña MM, Kauer-Sant'Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry 2008;69:1589-601.
10. NICE clinical guideline 38. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. 2006. Available online at www.nice.org.uk/CG038.
11. Thase ME. Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat 2008;4:21-31. (Pubitemid 351460976)
12. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjuntive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-22. (Pubitemid 46658703)
13. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162:1805-19. (Pubitemid 41428610)
14. Arieli A, Lepkifker E. The antidepressant effect of lithium. Curr Develop Psychopharmacol 1981;6:165-190.
15. Heit F, Nemeroff CB. Lithium augmentation of antidepressants in treatment refractory depression. J Clin Psychiatry 1998;59:28-33.
16. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005;85:259-66. (Pubitemid 40386509)
17. Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, Kemp DE, Kelley ME, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebocontrolled pilot study. J Clin Psychiatry 2007;68:1840-4.
18. Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008;10:323-33. (Pubitemid 351637697)
19. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88. (Pubitemid 37429647)
20. Agencia Europea de Medicamentos (EMEA). Ficha técnica de Zyprexa. En: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Zyprexa/emea-combined-h115es. pdf. Acceso: 10 de septiembre de 2009.
21. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium/divalproex as maintenance treatment for bipolar I disorder (international trial 126). J Affect Disord 2008;109:251-63.
22. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetapine in combination with lithium with quetiapine concomitant with lithium or divalproex (trial 127). Am J Psychiatry 2009;166:476-88.
23. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009:11: 225-55.
24. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60. (Pubitemid 40905587)
25. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression. A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-609. (Pubitemid 44772737)
26. Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D, Suppes D. Effectiveness of the new extended-release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (trial D144CC00002). Póster presentado en el 17 Congreso Europeo de Psiquiatría (ECP). Lisboa, Portugal. Enero 2009. www.infosnc.es. Abstract publicado en: European Psychiatry 2009;24: S574.
27. Olausson B, McElroy SL, Chang W, Paulsson B, Young AH. Placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I). Póster presentado en el International Forum of Mood and Anxiety Disorders (IFMAD). Viena, Austria. Noviembre 2008[a]. www.infosnc.es. Abstract publicado en: Int J Psychiatry Clin Pract 2008;12:343.
28. Olausson B, Young AH, Chang W, Paulsson B, Nordenhem A, McElroy SL. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN II). Póster presentado en el International Forum of Mood and Anxiety Disorders (IFMAD). Viena, Austria. Noviembre 2008[b]. www.infosnc.es. Abstract publicado en: Int J Psychiatry Clin Pract 2008;12:341-2.
29. Olausson B, Young AH, McElroy SL, Chang W, Nordenhem A, Paulsson B. Quetiapine monotherapy up to 52 weeks in patients with bipolar depression: continuation phase data from the EM-BOLDEN I and II studies. Póster presentado en el International Forum of Mood and Anxiety Disorders (IFMAD). Viena, Austria. Noviembre 2008[c]. www.infosnc.es. Abstract publicado en: Int J Psychiatry Clin Pract 2008;12:344.
30. De Vane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001;40:509-22.
31. Winter HR, Earley WR, Hamer-Maanson JE, Davis PC, Smith MA. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adol Psychopharmacol 2008;18:81-98. (Pubitemid 351311245)
32. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics. A critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46:359-88. (Pubitemid 46686464)
33. Figueroa C, Brecher M, Hammer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Progr Neuropsychopharmacol Biol Psychiatry 2009;33:199-204.
34. Möller HJ, Johnson S, Mateva T, Brecher M, Svensson O, Miller F, et al. Evaluation of the feasibility of switching from quetiapine immediate release to quetiapine extended release in stable outpatients with schizophrenia. Int Clin Psychopharmacol 2008;23:95-105. (Pubitemid 351317282)
35. Datto C, Berggren L, Patel JB, Eriksson H. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Therap 2009;31:492-502.
36. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005;66:40-48. (Pubitemid 40934073)
37. Montgomery SA. The under-recognize role of dopamine in the treatment of major depressive disorder. Int Clin Psychopharmacol 2008;23:63-9. (Pubitemid 351317278)
38. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007;64:327-36.
39. Brugue E, Vieta E. Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Progr Neuropsychopharmacol Biol Psychiatry 2007;31:275-82. (Pubitemid 44959242)
40. Newberg AR, Catapano LA, Zarate CA, Manji HK. Neurobiology of bipolar disorder. Expert Rev Neurotherapeutics 2008;8:93-110.
41. Stephen M Stahl. Stahl's essential psychopharmacology. Neuroscientific basis and practical applications. 3th edition. NY, USA: Cambridge University Press, 2008.
42. Goldberg JF, Burdick KD, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexol added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-6. (Pubitemid 38326114)
43. Sailer CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:285-92. (Pubitemid 23278291)
44. Gefvert O, Bergström M, Langström B, et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology 1998;135:119-26. (Pubitemid 28055494)
45. Jensen NH, Rodriguiz RM, Carón MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacol 2008;33:2303-12.
46. Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol 2009; doi: 10.1016/j. ejphar.2009.02.007.
47. Goldstein JM, Christoph G, Brecher M, Mclntyre RS. Unique mechanism of action of quetiapine in bipolar depression. Poster del 46th Annual Meeting of the American College of Neuropsychopharmacology. Diciembre, 2007. Boca Raton, USA. www.infosnc.es.
48. Möller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics. Two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci 2005;255:190-201.
49. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology 2002;161:263-70. (Pubitemid 34591664)
50. Mclntyre RS, Soczynska JK, Woldeyohannes HO. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007;8:1211-19. (Pubitemid 47034411)
51. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-9. (Pubitemid 32205190)
52. De Vry, J. 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacol 1995;121:1-26.
53. Blier P, Abbott FV. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 2001;26:37-43. (Pubitemid 32185178)
54. Becker OM, Dhanoa DS, Marantz Y, et al. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist for the treatment of anxiety and depression. J Med Chem 2006;49:3116-35. (Pubitemid 43830511)
55. Bremner JD, Meena N, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry 2000;157:115-8.
56. Jacobs BL, Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 2000;5:262-9. (Pubitemid 30438401)
57. Ichikawa J, Li Z, Dai L, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Research 2002:956: 349-57. (Pubitemid 35351402)
58. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001;76:1521-31. (Pubitemid 32198256)
59. Lieberman JA, Javiteh JA, Moore H. Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry 2008;165:931-36.
60. Ragozzino ME, Mohler EG, Prior M, Palencia CA, Rozman S. Acetylcholine activity in selective striatal regions supports behavioral flexibility. Neurobiol Learn Mem 2009;91:13-22.
61. García-Sevilla JA, Guimon J, García-Vallejo P, Fuster MJ. Biochemical and functional evidence of supersensitive platelet alpha 2-adrenoceptors in major affective disorder. Effect of long-term lithium carbonate treatment. Arch Gen Psychiatry 1986;43:51-57. (Pubitemid 16148971)
62. Meana JJ, García-Sevilla JA. Increased alpha 2-adrenoceptor density in the frontal cortex of depressed suicide victims. J Neural Trasm 1987;70:377-81. (Pubitemid 18022486)
63. González-Maeso J, Rodríguez-Puertas R, Meana JJ, García-Sevilla JA, Guimón J. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha (2A)-adrenoceptors. Mol Psychiatry 2002;7:755-67. (Pubitemid 34984953)
64. Ortega JE, Callado LF, Meana JJ. El sistema noradrenérgico en la neurobiología de la depresión. Psiq Biol 2008;15:162-74.
65. Mateo Y, Pineda J, Meana JJ. Somatodendritic alpha2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J Neurochem 1998;71:790-8. (Pubitemid 28480428)
66. Tascedda F, Lovati E, Blom JMC, Muzzioli P, Brunello N, Racagni G, et al. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic Seroquel (quetiapine fumarate). Neuropsychopharmacology 1999;21:211-7. (Pubitemid 29304582)
67. Eastwood SI, Burnet PWJ, Harrison PJ. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia. Mol Brain Res 1997;44:92-8.
68. Tarazi FI, Baldessarini RJ, Kula NS, Zhang K. Long term-effects of olanzapine, risperidone and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2003;306:1145-51. (Pubitemid 37025325)
69. Tarazi FI, Florijn WJ, Creese I. Regulation of inotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 1996;128:371-9. (Pubitemid 26417679)
70. Miller DD. Atypical antisychotics: sleep, sedation, and efficacy. Primary Care Companion J Clin Psychiatry 2004;6:3-7.
71. Xu H, Chen Z, He J, Haimanot S, Li X, Dick L, et al. Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus 2006;16:551-9. (Pubitemid 43942103)
72. Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res 2005;1063:32-39. (Pubitemid 41628205)
73. Chen Z, Xu H, Haimano S, Li X, Li XM. Quetiapine and venlafaxine synergically regulate heme oxygenase-2 protein expression in the hippocampus of stressed rats. Neurosci Lett 2005;389:173-7. (Pubitemid 41267221)
74. Sperner-Unterweger B. Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs 2005;65:1493-520. (Pubitemid 41124305)
75. Pérez-Neri I, Ramírez-Bermúdez J, Montes S, Ríos C. Possible mechanisms of neurodegeneration in schizophrenia. Neurosci Lett 2996;208:1-4.
76. Bian Q, Kato T, Monji A, Hashioka S, Mizoguchi Y, Horikawa H, et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-γ. Progr Neuropsychopharmacol Biol Psychiatry 2008;32:42-48.